MOUNTAIN VIEW, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for labeling changes pertaining to the use of bipolar radio frequency (RF) NovaSure Impedance Controlled Endometrial Ablation following a successful Essure Confirmation Test.
